Salivary Transcriptomic Biomarkers for Detection of Resectable Pancreatic Cancer

Overview

Journal Gastroenterology

Specialty Gastroenterology

Date 2009 Nov 26

PMID 19931263

Citations 147

Authors

Lei Zhang

James J Farrell

Hui Zhou

David Elashoff

David Akin

No-Hee Park

David Chia

David T Wong

Affiliations

Soon will be listed here.

Abstract

Background & Aims: Lack of detection technology for early pancreatic cancer invariably leads to a typical clinical presentation of incurable disease at initial diagnosis. New strategies and biomarkers for early detection are sorely needed. In this study, we have conducted a prospective sample collection and retrospective blinded validation to evaluate the performance and translational utilities of salivary transcriptomic biomarkers for the noninvasive detection of resectable pancreatic cancer.

Methods: The Affymetrix HG U133 Plus 2.0 Array (Affymetrix, Santa Clara, CA) was used to profile transcriptomes and discover altered gene expression in saliva supernatant. Biomarkers discovered from the microarray study were subjected to clinical validation using an independent sample set of 30 pancreatic cancer patients, 30 chronic pancreatitis patients, and 30 healthy controls.

Results: Twelve messenger RNA biomarkers were discovered and validated. The logistic regression model with the combination of 4 messenger RNA biomarkers (KRAS, MBD3L2, ACRV1, and DPM1) could differentiate pancreatic cancer patients from noncancer subjects (chronic pancreatitis and healthy control), yielding a receiver operating characteristic plot, area under the curve value of 0.971 with 90.0% sensitivity and 95.0% specificity.

Conclusions: The salivary biomarkers possess discriminatory power for the detection of resectable pancreatic cancer, with high specificity and sensitivity. This report provides the proof of concept of salivary biomarkers for the noninvasive detection of a systemic cancer and paves the way for prediction model validation study followed by pivotal clinical validation.

Citing Articles

Comparison of miRNA Profiles of Primary Tumors and Metastatic Tumors of Salivary Gland Tumors and Their Role in Prognosis: A Systematic Review.

Mohtasham N, Tarrah M, Arab F, Sadeghi M, Mohajertehran F Iran J Public Health. 2024; 53(9):1992-2005.

PMID: 39429675 PMC: 11490322. DOI: 10.18502/ijph.v53i9.16453.

Salivary biomarkers: a promising approach for predicting immunotherapy response in head and neck cancers.

Nejat Dehkordi A, Maddahi M, Vafa P, Ebrahimi N, Aref A Clin Transl Oncol. 2024; .

PMID: 39377974 DOI: 10.1007/s12094-024-03742-8.

Comparison between standard hematological parameters and blood doping biomarkers in dried blood spots within the athlete population of Swiss Sport Integrity.

Oliveira J, Loria F, Schobinger C, Kuuranne T, Mumenthaler C, Leuenberger N Front Sports Act Living. 2024; 6:1452079.

PMID: 39364095 PMC: 11446872. DOI: 10.3389/fspor.2024.1452079.

Development and validation of a non-invasive method for quantifying amino acids in human saliva.

Hasan M, Razu M, Akter S, Mou S, Islam M, Khan M RSC Adv. 2024; 14(31):22292-22303.

PMID: 39010921 PMC: 11247435. DOI: 10.1039/d4ra01130a.

Alterations of mannosylated glycopatterns recognized by Hippeastrum hybrid lectin in saliva of patients with lung cancer.

Zhang F, Xie M, Tang Z, Wang Y, Du J, Yu H Clin Oral Investig. 2024; 28(7):360.

PMID: 38847917 DOI: 10.1007/s00784-024-05751-x.

References

Okahara F, Ikawa H, Kanaho Y, Maehama T . Regulation of PTEN phosphorylation and stability by a tumor suppressor candidate protein. J Biol Chem. 2004; 279(44):45300-3. DOI: 10.1074/jbc.C400377200. View

Canto M, Goggins M, Yeo C, Griffin C, Axilbund J, Brune K . Screening for pancreatic neoplasia in high-risk individuals: an EUS-based approach. Clin Gastroenterol Hepatol. 2004; 2(7):606-21. DOI: 10.1016/s1542-3565(04)00244-7. View

Pellegata N, Sessa F, Renault B, Bonato M, Leone B, Solcia E . K-ras and p53 gene mutations in pancreatic cancer: ductal and nonductal tumors progress through different genetic lesions. Cancer Res. 1994; 54(6):1556-60. View

Canto M, Goggins M, Hruban R, Petersen G, Giardiello F, Yeo C . Screening for early pancreatic neoplasia in high-risk individuals: a prospective controlled study. Clin Gastroenterol Hepatol. 2006; 4(6):766-81. DOI: 10.1016/j.cgh.2006.02.005. View

Firpo M, Gay D, Granger S, Scaife C, DiSario J, Boucher K . Improved diagnosis of pancreatic adenocarcinoma using haptoglobin and serum amyloid A in a panel screen. World J Surg. 2008; 33(4):716-22. PMC: 2656575. DOI: 10.1007/s00268-008-9853-9. View

Smith J, Tachibana I, Pohl U, Lee H, Thanarajasingam U, Portier B . A transcript map of the chromosome 19q-arm glioma tumor suppressor region. Genomics. 2000; 64(1):44-50. DOI: 10.1006/geno.1999.6101. View

Rulyak S, Kimmey M, Veenstra D, Brentnall T . Cost-effectiveness of pancreatic cancer screening in familial pancreatic cancer kindreds. Gastrointest Endosc. 2003; 57(1):23-9. DOI: 10.1067/mge.2003.28. View

Nussbaumer C, Gharehbaghi-Schnell E, Korschineck I . Messenger RNA profiling: a novel method for body fluid identification by real-time PCR. Forensic Sci Int. 2005; 157(2-3):181-6. DOI: 10.1016/j.forsciint.2005.10.009. View

Okahara F, Itoh K, Nakagawara A, Murakami M, Kanaho Y, Maehama T . Critical role of PICT-1, a tumor suppressor candidate, in phosphatidylinositol 3,4,5-trisphosphate signals and tumorigenic transformation. Mol Biol Cell. 2006; 17(11):4888-95. PMC: 1635402. DOI: 10.1091/mbc.e06-04-0301. View

10.

Hu S, Arellano M, Boontheung P, Wang J, Zhou H, Jiang J . Salivary proteomics for oral cancer biomarker discovery. Clin Cancer Res. 2008; 14(19):6246-52. PMC: 2877125. DOI: 10.1158/1078-0432.CCR-07-5037. View

11.

Park N, Zhou X, Yu T, Brinkman B, Zimmermann B, Palanisamy V . Characterization of salivary RNA by cDNA library analysis. Arch Oral Biol. 2006; 52(1):30-5. PMC: 2743855. DOI: 10.1016/j.archoralbio.2006.08.014. View

12.

Goldenberg R, Culhane J . Preterm birth and periodontal disease. N Engl J Med. 2006; 355(18):1925-7. DOI: 10.1056/NEJMe068210. View

13.

Bigler L, Streckfus C, Copeland L, Burns R, Dai X, Kuhn M . The potential use of saliva to detect recurrence of disease in women with breast carcinoma. J Oral Pathol Med. 2002; 31(7):421-31. DOI: 10.1034/j.1600-0714.2002.00123.x. View

14.

Paster B, Boches S, Galvin J, Ericson R, Lau C, Levanos V . Bacterial diversity in human subgingival plaque. J Bacteriol. 2001; 183(12):3770-83. PMC: 95255. DOI: 10.1128/JB.183.12.3770-3783.2001. View

15.

Locker G, Hamilton S, Harris J, Jessup J, Kemeny N, Macdonald J . ASCO 2006 update of recommendations for the use of tumor markers in gastrointestinal cancer. J Clin Oncol. 2006; 24(33):5313-27. DOI: 10.1200/JCO.2006.08.2644. View

16.

Li Y, Zhou X, St John M, Wong D . RNA profiling of cell-free saliva using microarray technology. J Dent Res. 2004; 83(3):199-203. DOI: 10.1177/154405910408300303. View

17.

Park N, Li Y, Yu T, Brinkman B, Wong D . Characterization of RNA in saliva. Clin Chem. 2006; 52(6):988-94. PMC: 7108156. DOI: 10.1373/clinchem.2005.063206. View

18.

Michaud D, Joshipura K, Giovannucci E, Fuchs C . A prospective study of periodontal disease and pancreatic cancer in US male health professionals. J Natl Cancer Inst. 2007; 99(2):171-5. DOI: 10.1093/jnci/djk021. View

19.

Edgar R, Barrett T . NCBI GEO standards and services for microarray data. Nat Biotechnol. 2006; 24(12):1471-2. PMC: 2270403. DOI: 10.1038/nbt1206-1471. View

20.

Mager D, Haffajee A, Devlin P, Norris C, Posner M, Goodson J . The salivary microbiota as a diagnostic indicator of oral cancer: a descriptive, non-randomized study of cancer-free and oral squamous cell carcinoma subjects. J Transl Med. 2005; 3:27. PMC: 1226180. DOI: 10.1186/1479-5876-3-27. View